Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.

Lenvatinib is a prescription medication used to treat people with differentiated thyroid cancer (DTC a type of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing.

Lenvima is also used in combination with everolimus in patients with advanced renal cell carcinoma who had previously received an anti-angiogenic therapy.

Lenvatinib comes in a capsule form and is taken once daily with or without food.

If you miss a dose take the missed dose as soon as you remember. If your next dose is due within 12 hours skip the missed dose and take the next dose at your regular time.

Take this medication exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.

The dose your doctor recommends may be based on other medical conditions you have.

The recommended dose of lenvatinib for the treatment of metastatic thyroid cancer is 24 mg once daily.

The recommended dose of lenvatinib for the treatment of renal cell cancer is 18 mg once daily. It is to be given with 5 mg of everolimus.